Beta-lactam Allergy | Extended Open Challenge in Patients With a History of Drug Eruption Following Beta-lactam Treatment

Beta-lactam Allergy research study

What is the primary objective of this study?

Beta-lactam allergy is the most prevalent drug allergy. Drug eruption is the most common symptom whereas life-threatening anaphylaxis is rather rare. A recently published study (Journal of Allergy and Clinical Immunology, January 2011, Vol. 127, p. 218-222) described the safety of a 2-day oral beta-lactam challenge in penicillin-allergic patients, disregarding their penicillin skin test results. In the proposed study the investigators will similarly challenge beta-lactam allergic patients, both children and adults for an extended (5 days) period of time. The study will include patients with a history of a skin rash following beta-lactam administration as well as patients who cannot provide any data on their presumed allergic reaction, disregarding their penicillin skin test results.

Who is eligible to participate?

Inclusion Criteria: - History of skin rash following the administration of beta-lactam antibiotic - Patients with a diagnosis of penicillin allergy who have no data on the nature of the symptoms that have eventually resulted in establishing this diagnosis Exclusion Criteria: - Patients in whom the rash appeared within 1 hour after the last dose of the drug - Patients who also developed other anaphylactic symptoms - Patients who had a life-threatening rash such as Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis or DRESS. - Pregnancy

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Beta-lactam Allergy

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:Beta-lactam oral challengeOral daily dose, according to patient's weight, of amoxicillin or other suspected beta-lactam will be administered for 5 consecutive days

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Study Status


Start Date: March 2012

Completed Date: June 2015

Phase: N/A

Type: Interventional


Primary Outcome: The safety of a 5-day oral challenge in patients with suspected beta-lactam allergy

Secondary Outcome:

Study sponsors, principal investigator, and references

Principal Investigator:

Lead Sponsor: Meir Medical Center


More information:

Discuss Penicillin